AUTOLUS THERAPEUTICS PLC

AUTL NASDAQ
10.50
-0.11
-1.04%
After Hours: 10.50 0 0.00% 16:00 08/23 EDT
Open
10.57
Prev Close
10.61
High
11.05
Low
10.31
Volume
770.50K
Avg Vol (3M)
146.85K
52 Week High
53.24
52 Week Low
9.53
% Turnover
2.04%
Market Cap
396.64M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers AUTOLUS THERAPEUTICS PLC AUTL stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Autolus Therapeutics plc, formerly Autolus Therapeutics Limited, is a development-stage biopharmaceutical company. The company is engaged in developing programmed T-cell therapies for the treatment of cancer. The Company's clinical-stage product candidates target hematological cancers. Its products candidates include AUTO2, AUTO3, AUTO4, and AUTO6. AUTO2 is a dual-targeting programmed T-cell therapy for the treatment of relapsed or refractory multiple myeloma targeting B-cell Maturation Antigen and the transmembrane activator. AUTO3 is a T-cell therapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma and pediatric relapsed acute B lymphocytic leukemia. Its AUTO4 is a T-cell therapy for the treatment of peripheral T-cell lymphoma.
MORE >

Recently

Name
Price
%Change